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A rapid estimation of mutation frequency in
tumours would be invaluable in cancer manage-
ment. Considerable evidence suggests that drug
resistance in tumours frequently arises as a
consequence of spontaneous somatic mutation
(Goldie & Coldman, 1979) and therefore the
mutation rate of a tumour will be an index of the
potential to develop drug resistance. Previous
studies have compared the mutation rates of cell
lines using cloning assays. Cifone & Fidler (1981)
reported a higher mutation rate in metastatic
variant of UV-2237 fibrosarcoma cells than in a
clone of the same cell line with lower metastatic
potential. Warren et al. (1981) reported that
fibroblasts from patients with Bloom syndrome,
which predisposes individuals to various cancers,
had a 10-15 fold higher mutation rate than did
fibroblasts from normal individuals. These findings
have been important in correlating malignant
capacity with genetic instability, but unfortunately,
the techniques used have limited general application
since few human tumour cells will form colonies on
plastic. An alternative assay, soft agar cloning, has
also been used for the determination of mutation
rates in a variety of mammalian cell lines, including
Chinese hamster ovary cells (Li & Shimizu, 1983)
and the L5178Y mouse lymphoma cell line (Irr &
Snee, 1982). Again, the low cloning efficiency of
human tumour cells in soft agar (Hamburger et al.,
1978) and the fact that this method selects only
mutant cells which clone in agar limits the use of
this assay to determine mutation frequency in
human tumours. This latter source of error might
bias the estimation of the mutation rate in favour
of more malignant cells, which generally have
higher cloning efficiencies (Elmore et al., 1983).
Morley et al. (1983) and Albertini et al. (1982)
have reported a limiting dilution technique for the
measurement of mutation frequency in human
lymphocytes. Culture conditions have been
optimised for peripheral blood lymphocytes and a
cloning efficiency of 20-60% has been obtained.
Problems have been encountered, however, in
studies of cultured lymphoblast lines with variable
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cloning efficiencies and different growth factor
requirements (Seshadri et al., 1984).
We have prepared a monoclonal antibody to
bromodeoxyuridine (BrUdR) which recognises
BrUdR-substituted DNA. BrUdR is a thymidine
analogue readily incorporated into DNA by
proliferating cells. Cells which incorporate BrUdR
after exposure to a lethal concentration of a
cytotoxic drug must be drug resistant and may be
identified as such by the monoclonal antibody using
immunofluorescence techniques. If the drug used is
a selective agent for cells with a specific somatic
mutation e.g. the purine analogue 6-thioguanine (6-
TG) which selects for cells with a mutation at the
hypoxanthine- guanine phosphoribosyltransferase
(HGPRT) locus, then a measure of mutant
frequency is obtained.
The monoclonal antibody to BrUdR was derived
from the fusion of SP2/0-Agl4 cells (Shulman et
al., 1978) to spleen cells from BALB/c mice im-
munized with bromouridine conjugated to bovine
serum albumin (BSA) (K6hler & Milstein, 1975;
Erlanger & Beiser, 1964). The antibody with highest
affinity and specificity for BrUdR in the DNA
strand was chosen using a competitive enzyme
linked immuno-sorbent assay (ELISA) (Voller et
al., 1978). Although this antibody identifies cells
incorporating BrUdR after only minutes of
exposure, an incubation period equivalent to one
cell cycle time ensures that all cycling cells will have
traversed S-phase and thus incorporated BrUdR
into DNA. A fluorescence histogram of cells
exposed to BrUdR for one cell cycle time is shown
in Figure 1. Superimposed on this histogram of a
highly fluorescent cell population is the background
fluorescence peak obtained from stained cells which
had not been exposed to BrUdR. This fluorescence
is identical to the autofluorescence produced by
unstained cells (not shown), indicating negligible
non-specific binding of the anti-BrUdR antibody.
BrUdR incorporation and subsequent fluorescent
staining, was used to investigate the 6-TG dose
response relationships flow cytometrically. The dose
reponse curves illustrated in Figure 2 show that for
CCRF-CEM cells a concentration of over 30pM6-
TG for 72h is necessary to stop DNA synthesis
completely in 'wild type' cells. The dose-response












Figure 1 Immunofluorescent staining of proliferating
cells exposed to BrUdR. CCRF-CEM cells, a human
leukaemia T-cell line, growing exponentially in RPMI-
1640 medium supplemented with glutamine and 10%
foetal calf serum, were exposed to 10- M BrUdR for
24h (equivalent to one cell cycle). This exposure was
shown to have no affect on the growth rate or cell
cycle phase distribution of these cells. Cells (2 x 106)
were washed, resuspended in 5ml of PBS and slowly
syringed into 15ml of cold, vortexing ethanol. The
fixed cell suspensions were kept at 4°C until staining.
The fixed cells were pelleted and the DNA denatured
in situ by resuspension in 1 ml of 1.5 MHCI. After
20min at room temperature the cells were washed in
cold saline/1% Tween 20 (polyoxyethylene sorbitan
monolaurate, Sigma, St Louis, MO, USA) and in-
cubated for 30min at 37°C with protein A purified
anti-BrUdR antibody 200 pgml- 1, was made up in
PBS/1% BAS/1% Tween 20. The cells were washed in
this buffer and incubated with sheep F(ab')2 anti-
mouse Ig-fluorescein conjugated (from New England
Nuclear, Boston, Massachusetts) 100 p1 at 250 gml- 1,
for 60min at 37°C. After a final wash the cells were
resuspended in buffer and the fluorescence measured
using a fluorescence-activated cell sorter (FACS III,
Becton Dickinson, Sunnyvale, Ca, USA). The laser
was tuned to 488 nm at 400mW. M represents control
fluorescence from staining cells not exposed to
BrUdR.
relationship detected by this assay is in close
agreement with the results for peripheral blood
lymphocytes and human skin fibroblast lines
reported by others using limiting dilution and
cloning assays, respectively (Albertini et al., 1982;
Elmore et al., 1983). Using this information,
conditions chosen for the detection of resistant cells
were 72h exposure to 100gM6-TG. This treatment
is toxic to wild-type CCRF-CEM cells, but the
growth rate of a mutant CCRF-CEM sub-line,






10 30 60 100 300
6-Thioguanine (>iM)
Figure 2 6-thioguanine dose-response curves. Exponen-
tially growing CCRF-CEM cells were exposed to
varying concentrations of 6-TG for 48h (A) and 72h
(@). 10 5MBrUdR was added to each flask 24h
prior to harvesting. This exposure to BrUdR had no
effect on the growth of control cells, nor did it affect
the response of drug-treated cells. The cells were
washed, fixed and stained for BrUdR incorporation as
described in the legend of Figure 1. The surviving
fraction was determined from the proportion of
fluorescent cells as analysed using the FACS III. The
total number of cells in each sample and the
fluorescent population were determined by the
simultaneous measurement of forward light scatter and
fluorescence.
deficient in the enzyme HGPRT, is identical to that
of untreated control cells under these conditions
(data not shown).
Figure 3 illustrates fluorescence historgrams of
mutant, wild type and mixed cell populations
exposed to 6TG. Histogram (A) shows that the
HGPRT-1 mutants continue synthesizing DNA
normally in the presence of a high concentration of
6-TG which stops DNA synthesis in the wild-type
CCRF-CEM cells (B). In the latter case there is no
fluorescence peak indicating that the cells are not
incorporating BrUdR. Mixtures of mutants and
wild type CCRF-CEM cells in varying proportions
were exposed to 6-TG in order to investigate the
sensitivity of the BrUdR assay in the rapid
detection of low numbers of drug-resistant cells.
The histogram (C) is obtained from a mixture of
one HGPRT-1 mutant in 105 wild-type CCRF-
CEM cells. A small but easily distinguishable peak
of fluorescent cells was obtained, representingDETECTION OF DRUG RESISTANT CELLS BY IMMUNOFLUORESCENCE 635
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Figure 3 Fluorescence histograms obtained from a) HGPRT-1, a mutant subline of CCRF-CEM, b) the
'wild type' CCRF-CEM cells and c) a mixture of mutant in 105 non-mutant CCRF-CEM cells after
exposure to 10-4M 6-TG for 72h with 10-5M BrUdR added for the final 24h. The total number of
exponentially growing cells in each flask at the time of 6-TG addition was 1.7 x 107. The HGPRT-1 cells (a)
continued to cycle normally and at 72h, 2 x 106 cells were washed, fixed and stained for BrUdR
incorporation, as described in the legend to Figure 1. The entire contents of flasks depicted in b and c, were
harvested and stained, as substantial cell death had decreased the total number of whole cells (as determined
by haemocytometer count) to <2 x 106. The mutant cell population in c, has clearly expanded during this
period and although accurate quantitation is not yet possible at least 800 fluorescent cells are detected in the
histogram shown.
cycling mutant cells. The possibility of metabolic
co-operation between the resistant and sensitive
cells (Ochi et al., 1982) in mix experiments was
examined but no evidence of this phenomenon was
found. Accurate quantitation of rare cell sub-
populations such as the HGPRT-cells in a mix
experiment is being attempted using fluorescent
beads to determine sample volume and thus cell
number (Stewart & Steinkamp, 1982).
The BrUdR antibody method of identifying
drug-resistant cells has many potential advantages.
The method does not require high cloning efficiency
conditions and provided adequate concentrations of
6-TG are used for a sufficient exposure period to
kill sensitive cells, cells continuing to cycle can be
assumed to be HGPRT-. As in the autoradio-
graphic method for detection of 6-TG resistant
lymphocytes described by Strauss and Albertini
(1979), cells identified as 6-TG resistant by BrUdR
fluorescence cannot be proved to be mutants since
they cannot be clonally expanded and the HGPRT
activity measured. However Dempsey and Morley
(1983) have shown, in parallel cloning and auto-
radiographic mutation assays in peripheral blood
lymphocytes, that provided a 6-TG concentration
well along the plateau of the dose-response curve is
used, resistant cells measured autoradiographically
usually completely lack HGPRT.
This rapid and sensitive assay can be applied in a
wide range of cells. It will find an important place
not only as a drug resistance assay, measuring the
proportion of cells that are resistant to a chemo-
therapeutic agent, but also as a mutation assay
measuring the rates with which tumour cells acquire
drug resistance. Clearly the precise conditions for
studying drug resistance in human tumours remain
to the defined and currently we are using this
reagent to study biopsies of xenografted tumours.
The duration of drug exposure in vitro and the
timing of BrUdR addition may need to be varied
depending upon the cytotoxic drug being tested and
the growth fraction of the tumour. A similar anti-
body (Gratzner, 1982) has recently been used to
measure the proliferating cell fraction in vivo
(Morstyn et al., 1983) and to study cell cycle
perturbations (Dolbeare et al., 1983).
We are grateful to Elizabeth A. Musgrove for her advice
and technical expertise in flow cytometry, and to Judy
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